Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
GH Research ( (GHRS) ) has issued an announcement.
On February 4, 2025, GH Research PLC announced the pricing of its public offering in the United States, raising approximately $150 million through the sale of 10 million ordinary shares at $15 each. The offering, managed by Cantor, Stifel, and RBC Capital Markets, aims to enhance the company’s financial capabilities to advance its initiatives in the biopharmaceutical sector.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for depression, specifically targeting treatment-resistant depression with its proprietary mebufotenin therapies.
YTD Price Performance: 106.26%
Average Trading Volume: 288,508
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $936M
See more data about GHRS stock on TipRanks’ Stock Analysis page.
